Press Releases
Crescendo Biologics Announces First ‘Triple Knockout’ Mouse
29 September 2010
Crescendo Biologics Limited (Crescendo) today announces it has established a colony of engineered mice completely devoid of endogenous antibody polypeptides. The proprietary ‘triple knockout’ mice are believed to be unique and have the immunoglobulin heavy chain (IgH), kappa light chain and lambda light chain loci all functionally silenced by large-scale genomic deletion. Read more
Clive Dix Appointed as Chairman of Crescendo Biologics
8 January 2010
Crescendo Biologics (“Crescendo”) today announces the appointment of Clive Dix as Chairman. Dr Dix will work closely with Mike Romanos, Chief Scientific Officer of Crescendo, to drive the development of the Company and its proprietary antibody fragment technologies following the recent £4.5 million seed round fundraising. Read more
Crescendo Biologics Raises £4.5 million in Seed-Funding
Led by Sofinnova Partners
12 October 2009
Crescendo Biologics (“Crescendo”) today announces it has raised £4.5 million in a seed-funding round to advance the development of its fragment antibody technology platforms. The funding round was led by Sofinnova Partners, a Paris-based venture capital firm, with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating. Read more
Mike Romanos Appointed as CSO of Crescendo Biologics
12 October 2009
Mike Romanos has been appointed Chief Scientific Officer of Crescendo Biologics (“Crescendo”) and joins the Board as a Director. Dr Romanos will take leadership of the company and its proprietary antibody fragment technologies following a £4.5 million seed fundraising round led by Sofinnova Partners. Read more
Articles
Start-Up Profile
February 2010
By now everyone knows that antibodies can make excellent drugs. What is far less certain, albeit widely hoped, is if antibody fragments will also succeed in the clinic. The first wave of candidates is only now entering early clinical trials. Crescendo Biologics Ltd. is one of many firms betting that smaller will prove better: it aims to tailor single-domain fragments and optimize them with a ribosome-display platform. Read full article
BioCentury Emerging Company Profile
17 May 2010
Crescendo Biologics Ltd. believes its transgenic mouse antibody fragment technology combines the best characteristics of the two leading antibody fragment platforms — human origin and in vivo maturation — which should allow rapid creation of high affinity fragments. The company hopes to have clinical proof of concept (POC) in about three years. Read full article
Business Weekly: Cambridge research key to UK economy, says Minister
10 September 2010
Cambridge’s research base is the key to the UK’s economic future, Universities and Science Minister, David Willetts revealed in a visit to key science hubs in the city.He was in Cambridge to officially open the UK’s most powerful microscope, attend the topping out ceremony for a new £200m biological sciences laboratory and visit bioincubator facilities which provide support to early stage companies commercialising bioscience discoveries. Read full article